Impact of Type 2 Diabetes on the Plasma Levels of Vascular Endothelial Growth Factor and Its Soluble Receptors Type 1 and Type 2 in Patients with Peripheral Arterial Disease

Overview

Journal J Zhejiang Univ Sci B

Specialties Biology
General Medicine

Date 2015 Nov 6

PMID 26537213

Citations 9

Authors

Radoslaw Wieczor

Grazyna Gadomska

Barbara Ruszkowska-Ciastek

Katarzyna Stankowska

Jacek Budzynski

Jacek Fabisiak

Karol Suppan

Grzegorz Pulkowski

Danuta Rosc

Affiliations

Soon will be listed here.

Abstract

Objective: Type 2 diabetes coexistent with lower extremity artery disease (peripheral arterial disease (PAD)) can be observed in numerous patients. The mechanism compensating for ischemia and contributing to healing is angiogenesis-the process of forming new blood vessels. The purpose of this study was to assess the likely impact of type 2 diabetes on the plasma levels of proangiogenic factor (vascular endothelial growth factor A (VEGF-A)) and angiogenesis inhibitors (soluble VEGF receptors type 1 and type 2 (sVEGFR-1 and sVEGFR-2)) in patients with PAD.

Methods: Among 46 patients with PAD under pharmacological therapy (non-invasive), we identified, based on medical history, a subgroup with coexistent type 2 diabetes (PAD-DM2+, n=15) and without diabetes (PAD-DM2-, n=31). The control group consisted of 30 healthy subjects. Plasma levels of VEGF-A, sVEGFR-1, and sVEGFR-2 were measured using the enzyme-linked immunosorbent assay (ELISA) method.

Results: The subgroups of PAD-DM2+ and PAD-DM2- revealed significantly higher concentrations of VEGF-A (P=0.000 007 and P=0.000 000 1, respectively) and significantly lower sVEGFR-2 levels (P=0.02 and P=0.000 01, respectively), when compared with the control group. Patients with PAD and coexistent diabetes tended to have a lower level of VEGF-A and higher levels of sVEGFR-1 and sVEGFR-2 comparable with non-diabetic patients.

Conclusions: The coexistence of type 2 diabetes and PAD is demonstrated by a tendency to a lower plasma level of proangiogenic factor (VEGF-A) and higher levels of angiogenesis inhibitors (sVEGFR-1 and sVEGFR-2) at the same time. Regardless of the coexistence of type 2 diabetes, hypoxia appears to be a crucial factor stimulating the processes of angiogenesis in PAD patients comparable with healthy individuals, whereas hyperglycemia may have a negative impact on angiogenesis in lower limbs.

Citing Articles

Recent progress in bone-repair strategies in diabetic conditions.

Sheng N, Xing F, Wang J, Zhang Q, Nie R, Li-Ling J Mater Today Bio. 2023; 23:100835.

PMID: 37928253 PMC: 10623372. DOI: 10.1016/j.mtbio.2023.100835.

Effect of Revascularization on Intramuscular Vascular Endothelial Growth Factor Levels in Peripheral Arterial Disease.

Schawe L, Raude B, Carstens J, Hinterseher I, Hein R, Omran S Biomedicines. 2022; 10(2).

PMID: 35203679 PMC: 8962418. DOI: 10.3390/biomedicines10020471.

Peripheral vascular disease: preclinical models and emerging therapeutic targeting of the vascular endothelial growth factor ligand-receptor system.

Ganta V, Annex B Expert Opin Ther Targets. 2021; 25(5):381-391.

PMID: 34098826 PMC: 8573823. DOI: 10.1080/14728222.2021.1940139.

Growth Factor Deregulation and Emerging Role of Phosphatases in Diabetic Peripheral Artery Disease.

Mercier C, Rousseau M, Geraldes P Front Cardiovasc Med. 2021; 7:619612.

PMID: 33490120 PMC: 7817696. DOI: 10.3389/fcvm.2020.619612.

Evaluation of platelet-rich plasma from diabetic donors shows increased platelet vascular endothelial growth factor release.

Karina , Wahyuningsih K, Sobariah S, Rosliana I, Rosadi I, Widyastuti T Stem Cell Investig. 2020; 6:43.

PMID: 32039265 PMC: 6987324. DOI: 10.21037/sci.2019.10.02.

References

Lim H, Lip G, Blann A . Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis. 2005; 180(1):113-8. DOI: 10.1016/j.atherosclerosis.2004.11.004. View

Chung A, Hsiang Y, Matzke L, McManus B, van Breemen C, Okon E . Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res. 2006; 99(2):140-8. DOI: 10.1161/01.RES.0000232352.90786.fa. View

Liu W, Zhang X, Song C, Bao S, Lai D, Mou J . Expression and characterization of a soluble VEGF receptor 2 protein. Cell Biosci. 2014; 4(1):14. PMC: 3977943. DOI: 10.1186/2045-3701-4-14. View

Duh E, Aiello L . Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes. 1999; 48(10):1899-906. DOI: 10.2337/diabetes.48.10.1899. View

Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M . Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis. Cancer Sci. 2007; 98(3):405-10. PMC: 11158411. DOI: 10.1111/j.1349-7006.2007.00402.x. View

Zakareia F . Correlation of peripheral arterial blood flow with plasma chemerin and VEGF in diabetic peripheral vascular disease. Biomark Med. 2012; 6(1):81-7. DOI: 10.2217/bmm.11.85. View

Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich H . Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer. 2002; 98(1):14-8. DOI: 10.1002/ijc.10121. View

Skora J, Barc P, Pupka A, Dawiskiba T, Korta K, Albert M . Transplantation of autologous bone marrow mononuclear cells with VEGF gene improves diabetic critical limb ischaemia. Endokrynol Pol. 2013; 64(2):129-38. View

Meyer R, Mohammadi M, Rahimi N . A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. J Biol Chem. 2005; 281(2):867-75. PMC: 1360223. DOI: 10.1074/jbc.M506454200. View

10.

Orrico C, Pasquinelli G, Foroni L, Muscara D, Tazzari P, Ricci F . Dysfunctional vasa vasorum in diabetic peripheral artery obstructive disease with critical lower limb ischaemia. Eur J Vasc Endovasc Surg. 2010; 40(3):365-74. DOI: 10.1016/j.ejvs.2010.04.011. View

11.

Botti C, Maione C, Dogliotti G, Russo P, Signoriello G, Molinari A . Circulating cytokines present in the serum of peripheral arterial disease patients induce endothelial dysfunction. J Biol Regul Homeost Agents. 2012; 26(1):67-79. View

12.

Blann A, Belgore F, McCollum C, Silverman S, Lip P, Lip G . Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond). 2002; 102(2):187-94. View

13.

Fadini G, Miorin M, Facco M, Bonamico S, Baesso I, Grego F . Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005; 45(9):1449-57. DOI: 10.1016/j.jacc.2004.11.067. View

14.

Aref S, El Sherbiny M, Goda T, Fouda M, Al Askalany H, Abdalla D . Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology. 2005; 10(2):131-4. DOI: 10.1080/10245330500065797. View

15.

Hazarika S, Dokun A, Li Y, Popel A, Kontos C, Annex B . Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res. 2007; 101(9):948-56. DOI: 10.1161/CIRCRESAHA.107.160630. View

16.

Chang Y, Chang M, Wei S, Tien Y, Hsu C, Liang P . Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas. 2008; 37(2):145-50. DOI: 10.1097/MPA.0b013e318164548a. View

17.

Bao P, Kodra A, Tomic-Canic M, Golinko M, Ehrlich H, Brem H . The role of vascular endothelial growth factor in wound healing. J Surg Res. 2008; 153(2):347-58. PMC: 2728016. DOI: 10.1016/j.jss.2008.04.023. View

18.

Hochberg I, Hoffman A, Levy A . Regulation of VEGF in diabetic patients with critical limb ischemia. Ann Vasc Surg. 2001; 15(3):388-92. DOI: 10.1007/s100160010089. View

19.

Ruszkowska-Ciastek B, Sokup A, Socha M, Ruprecht Z, Halas L, Goralczyk B . A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus. J Zhejiang Univ Sci B. 2014; 15(6):575-81. PMC: 4116851. DOI: 10.1631/jzus.B1400024. View

20.

Jude E, Eleftheriadou I, Tentolouris N . Peripheral arterial disease in diabetes--a review. Diabet Med. 2010; 27(1):4-14. DOI: 10.1111/j.1464-5491.2009.02866.x. View